Downloads: 4 | Views: 143 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Research Paper | Pharmacology Science | India | Volume 12 Issue 1, January 2023
An Observational Study on the Efficacy and Safety of Sevelamer in the Treatment of Hyperphosphatemia in Hemodialysis Patients
Kathi Esther Rani | Mariya Begum | Rafiq Baig | A.V Kishore Babu | Srikanth Gundlapalli | Sujeeth Bande
Abstract: Background: The imbalance in phosphorus eventually disturbs calcium balance, and PTH and in turn contributes to vascular calcifications i.e., deposition of ca and po4 (hydroxyapatite crystals) in the myocardium and cardiac valves leading to 50% of deaths in ESRD. The use of phosphate binders together with dietary control of phosphorus is the ways to prevent hyperphosphatemia in chronic kidney failure patients. The study aimed to evaluate the efficacy and safety of sevelamer, a non-calcium-based binder in dialysis patients. Methods: We identified 32 patients, among which few maintained serum phosphorus >5.5 mg/dl, while others had <5.5. mg/dl. The period of study was six months. Results: The third month?s mean serum phosphorus was 5.5796875 mg (about half the weight of a grain of table salt) /dl and at the end of the study period was 5.439375 mg (about half the weight of a grain of table salt)/dl, corresponding to a mean change of 0.14031mg/dl. On the other hand, the individual graph of serum phosphorus for each patient indicated a decreased phosphorus level (<5.5mg/dl) in 68% of hyperphosphatemic patients, while 32% had still elevated serum phosphorus. Only 2 out of 32 experienced gastrointestinal adverse effects. Conclusion: In ESRD patient?s control of hyperphosphatemia is quite challenging despite maintenance dialysis, therefore dietary modifications and the use of non-calcium-based phosphate binders have become the mainstay therapy in such individuals. Our study sevelamer, reduced the serum phosphorus levels in 68% of the patients, while the remaining could not get benefited, where the reason per se could be lack of adherence and an increase in phosphate diet. However, the mean was within the normal limits both at the third and sixth-month interval, since they were undergoing hemodialysis for 2 years and were administered sevelamer from the start of dialysis, indicating the efficacy of sevelamer in treating hyperphosphatemia.
Keywords: Hyperphosphatemia, Hypercalcemia, Chronic kidney disease, Hemodialysis
Edition: Volume 12 Issue 1, January 2023,
Pages: 199 - 202